The role of immunoglobulin replacement therapy in managing primary immunodeficiency

Abstract

Primary immunodeficiency (PID) encompasses a diverse group of disorders characterized by defects in the immune system, leading to increased susceptibility to infections, autoimmune diseases, and malignancies. Immunoglobulin replacement therapy (IRT) has become a cornerstone in managing these conditions, offering a lifeline to patients with antibody deficiencies. This review comprehensively examines the role of IRT in managing PID, exploring its mechanisms of action, clinical efficacy, administration methods, and potential complications. By synthesizing evidence from various secondary sources, this paper aims to provide a detailed understanding of the therapeutic benefits and challenges associated with IRT in PID management, contributing to improved patient outcomes and informed clinical practices.